monarchE鏄竴椤瑰叏鐞冦€侀殢鏈恒€佸紑鏀炬爣绛俱€佸弻闃熷垪銆佸涓績III鏈熶复搴婄爺绌讹紝鍏卞叆缁�5,637渚嬫穻宸寸粨闃虫€х殑HR+, HER2-楂樺鍙戦闄╂棭鏈熶钩鑵虹檶锛圗BC锛夋偅鑰呫€傝鐮旂┒鐨勫彈璇曞璞℃潵鑷�38涓浗瀹剁殑600澶氫釜鐮旂┒涓績锛屾槸涓€椤逛笓闂ㄩ拡瀵笴DK4 & 6鎶戝埗鍓傝緟鍔╂不鐤楁穻宸寸粨闃虫€с€侀珮鍗盓BC鎮ｈ€呯殑涓村簥鐮旂┒銆傜爺绌跺叆缁勬爣鍑嗕负鎮ｈ€呯梾鐞嗛槼鎬ц厠绐濇穻宸寸粨(ALN)鈮�4涓紝鎴栭槼鎬ц厠绐濇穻宸寸粨鏁颁负1鑷�3涓笖鑷冲皯鍏锋湁浠ヤ笅涓€绉嶉珮椋庨櫓鐗瑰緛锛氬師鍙戣偪鐦も墺5cm锛涜偪鐦ょ粍缁囧鍒嗙骇3绾э紱Ki-67鈮�20%銆傚彈璇曡€呮寜1:1鐨勬瘮渚嬭闅忔満鍒嗛厤鑷抽樋璐濊タ鍒╋紙150 mg锛屾瘡鏃ヤ袱娆★級鑱斿悎鏍囧噯杈呭姪鍐呭垎娉屾不鐤楃粍锛坣=2808锛夛紝鎴栧崟绾爣鍑嗚緟鍔╁唴鍒嗘硨娌荤枟缁勶紙n=2829锛夛紝娌荤枟鏈熶负2骞淬€傛墍鏈夋偅鑰呭皢鏍规嵁涓村簥鎸囧緛鎸佺画鎺ュ彈鑷冲皯5骞寸殑杈呭姪鍐呭垎娉屾不鐤椼€傜爺绌剁殑涓昏鐮旂┒缁堢偣涓烘棤娴告鼎鎬х柧鐥呯敓瀛樻湡(IDFS)銆傛牴鎹笓瀹舵寚鍗楋紝璇ユ寚鏍囩殑瀹氫箟涓鸿嚦鐧岀棁澶嶅彂銆佹柊鍙戠檶鐥囨垨姝讳骸鐨勬椂闂淬€�<\/p> \n

鎹及璁★紝90%鐨勪钩鑵虹檶纭瘖鍦ㄦ棭鏈�^{[1]<\/sup>銆傚叾涓渶甯歌鐨勪簹鍨嬩负HR+, HER2-鍨嬶紝绾﹀崰涔宠吅鐧屾偅鑰呮€绘暟鐨�70%^{[2]<\/sup>銆傚敖绠R+, HER2-鍨嬫棭鏈熶钩鑵虹檶鎮ｈ€呯殑棰勫悗閫氬父杈冨ソ锛屼絾浠嶆湁鎮ｈ€呭彲鑳藉鍙戞垨鍑虹幇杩滃杞Щ鎴愪负涓嶅彲娌绘剤鐨勭柧鐥咃紝楂樺嵄鏃╂湡涔宠吅鐧屾偅鑰呭鍙戦闄╂槸闈為珮鍗辨偅鑰呯殑3鍊�^{[3]<\/sup>銆傚湪鍐呭垎娉屾不鐤楃殑鍓嶄袱骞达紝杩欑被鎮ｈ€呮湁鏇撮珮鐨勫鍙戦闄┿€�<\/p> \n}}}

涓嶩R+, HER2-鏃╂湡涔宠吅鐧屽鍙戠浉鍏崇殑楂樺嵄鍥犵礌鍖呮嫭锛氶槼鎬ф穻宸寸粨鐘舵€併€侀槼鎬ф穻宸寸粨鏁伴噺銆佽偪鐦や綋绉ぇ锛堚墺5cm锛夊拰鑲跨槫缁勭粐瀛﹀垎绾ч珮锛�3绾э級銆傛穻宸寸粨闃虫€ф剰鍛崇潃鍦ㄤ钩鎴块檮杩戠殑娣嬪反缁撲腑鍙戠幇浜嗘潵鑷钩鎴胯偪鐦ょ殑鐧岀粏鑳炪€傝櫧鐒朵钩鑵虹檶鍙互閫氳繃鎵嬫湳鍒囬櫎锛屼絾娣嬪反缁撲腑瀛樺湪鐧岀粏鑳炴剰鍛崇潃澶嶅彂鍜岃繙澶勮浆绉荤殑鍑犵巼鏇撮珮銆�<\/p> \n

鏍规嵁鏉ヨ嚜GLOBOCAN鐨勬暟鎹紝涔宠吅鐧屽凡瓒呰秺鑲虹檶鎴愪负鍏ㄧ悆鏈€甯歌鐨勭檶鐥囥€傛嵁浼拌锛�2020骞村叏鐞冧钩鑵虹檶鏂板彂鐥呬緥鏁颁负230涓囦緥锛岃繖鎰忓懗鐫€姣�8渚嬫柊璇婃柇鐧岀棁鎮ｈ€呬腑灏辨湁1渚嬩负涔宠吅鐧�^{[4]<\/sup>銆�2020骞达紝鍏ㄧ悆绾︽湁68.5涓囦緥涔宠吅鐧屾浜＄梾渚嬶紝涔宠吅鐧屾垚涓哄叏鐞冪浜斿ぇ鐧岀棁姝讳骸鍘熷洜^{[5]<\/sup>銆�<\/p> \n}}

鍏充簬鍞嫨<\/u><\/b>^{®<\/sup><\/u><\/b>锛堥樋璐濊タ鍒╃墖锛�<\/u><\/b><\/p> \n}

鍞嫨^{®<\/sup>锛堥樋璐濊タ鍒╃墖锛夊凡鑾锋壒鐢ㄤ簬閮ㄥ垎鐗瑰畾HR+, HER2-鍨嬩钩鑵虹檶鎮ｈ€呯殑杈呭姪娌荤枟锛屼互鍙婃櫄鏈熸垨杞Щ鎬ф偅鑰呯殑娌荤枟^{[6]<\/sup>銆傞樋璐濊タ鍒╂槸棣栦釜涔熸槸鍞竴涓€涓幏鎵圭敤浜庢不鐤楁穻宸寸粨闃虫€с€侀珮鍗辨棭鏈熶钩鑵虹檶锛圗BC锛夋偅鑰呯殑CDK4 & 6鎶戝埗鍓�^{[7]<\/sup>銆�<\/p> \n}}}

绀兼潵涓村簥寮€鍙戦」鐩殑鏁翠綋鐮旂┒缁撴灉杩涗竴姝ユ彁鍗囦簡闃胯礉瑗垮埄浣滀负CDK4 & 6鎶戝埗鍓傜殑鐙壒浼樺娍銆傞拡瀵归珮鍗辨棭鏈熶钩鑵虹檶锛岄樋璐濊タ鍒╁湪monarchE涓村簥鐮旂┒涓樉绀哄嚭瓒呰秺涓ゅ勾娌荤枟鏈熺殑鎸佺画鑾风泭锛岃繖涔熸槸涓€椤规棬鍦ㄤ笓闂ㄧ爺绌禖DK4 & 6鎶戝埗鍓傜敤浜庢穻宸寸粨闃虫€с€侀珮鍗盓BC鎮ｈ€呰緟鍔╂不鐤楃殑涓村簥鐮旂┒^{[8]<\/sup>銆傞拡瀵硅浆绉绘€т钩鑵虹檶锛岄樋璐濊タ鍒╁湪III鏈烳ONARCH 2鐮旂┒涓樉绀哄嚭鍏锋湁鏄捐憲缁熻瀛︽剰涔夌殑鎬荤敓瀛樻湡鑾风泭^{[9]<\/sup>銆傚湪鎵€鏈変复搴婄爺绌朵腑锛岄樋璐濊タ鍒╂樉绀哄嚭涓€鑷翠笖鏅亶鍙帶鐨勫畨鍏ㄦ€х壒寰併€傞櫎涔宠吅鐧屽锛岀ぜ鏉ヨ繕鍦ㄥ紑灞曢樋璐濊タ鍒╅拡瀵逛笉鍚岀被鍨嬮毦娌绘€у墠鍒楄吅鐧岀殑鐮旂┒銆�<\/p> \n}}

\n \n \n \n \n \n \n \n \n \n \n \n
^{[1] <\/sup>Howlander N, et al. SEER Cancer Statistics Review, 1975-2017, based on November 2019 SEER data submission. https:\/\/seer.cancer.gov\/archive\/csr\/1975_2017\/<\/a>. Accessed October 18, 2023.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[2] <\/sup>National Cancer Institute, SEER. Cancer Stat Facts: Female Breast Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html<\/a>. Accessed October 18, 2023.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[3] <\/sup>Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet<\/i>. 2005;365(9472):1687-1717. doi:10.1016\/S0140-6736(05)66544-0.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[4] <\/sup>Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin<\/i>. 2021;71(3):209-249.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[5]<\/sup> American Cancer Society. Cancer Statistics Center. http:\/\/cancerstatisticscenter.cancer.org<\/a>. Accessed October 18, 2023.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[6]<\/sup> Verzenio. Prescribing information. Lilly USA, LLC.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[7]<\/sup> Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^{®<\/sup>) for Breast Cancer V.4.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed October 18, 2023. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.<\/span><\/p> <\/td> \n <\/tr> \n}}
^{[8]<\/sup> Johnston SRD, Toi M, O'Shaughnessy J, Rastogi P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023 Jan;24(1):77-90.<\/span><\/p> <\/td> \n <\/tr> \n}
^{[9]<\/sup> Sledge GW Jr, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2鈥搉egative breast cancer that progressed on endocrine therapy鈥擬ONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6(1):116-124. doi:10.1001\/jamaoncol. 2019.4782.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n}
<\/p>"]; $("#dvExtra").html(content_array[0]);})();